Library/For Weight Loss/Orforglipron

RUO · Not ApprovedOral GLP-1For Weight LossPhase 3 Done+2 more

Orforglipron

An oral, non-peptide GLP-1 receptor agonist. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 10 minEvidence ●●●○○Citations 60

+ Add to Stack⚖ Compare

⚖ Compare side-by-side ⎙ Print companion card

Free — puts Orforglipron on your decision board.

The Orforglipron Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status

Research-only

Class

Oral GLP-1

Evidence

3/ 5●●●○○

FDA status

$19 ↓

Phase 3 ACHIEVE-1 (T2D, 36 mg, 40 wk)

$19 ↓

Phase 3 ATTAIN-1 (obesity, 36 mg, 72 wk)

$19 ↓

Read this if

you specifically need ORAL (needle aversion, travel, lifestyle adherence) — orforglipron is the only oral GLP-1 in late-stage development. Every other approved GLP-1 is injectable (oral semaglutide / Rybelsus exists but has a strict food-restriction window most people break)
you've been on injectable GLP-1s and you genuinely cannot stand needles anymore
you're tracking Lilly's pipeline and want to know when the pill arrives
you've tried oral semaglutide and the food-restriction window broke your routine

Skip this if

you want it now — it's not approved yet
you have a personal or family history of medullary thyroid carcinoma
you're shopping RUO orforglipron — small molecule, hard to verify identity, not worth the gamble

The 4 ways you can buy Orforglipron

No FDA-approved orforglipron yet.

Compounded 503A

✗

Not available

Not meaningfully available

Small-molecule oral; no realistic compounding path pre-approval.

RUO (research-only)

✓

Sold 'for research only'

$100–$250/mo

Small-molecule synthesis is hard to verify by mass spec; identity-failures likely common pre-appro…

Gray market

✓

Unregulated overseas import

Varies — not on user's vendor list

Small molecule — gray path is Chinese chemical suppliers, not the peptide raws this vendor list co…

Click any lane for the full Sourcing breakdown. Prices and lane availability vary by molecule — this is the per-peptide snapshot, not a generic table.

First 90 days · Orforglipron

What we'd actually do

Weeks 1–2

GI side effects start. Nausea is the rate-limiter. Don't titrate up if you can't tolerate the starting dose — the side-effect curve gets steeper, not flatter.

Weeks 4–8

Appetite suppression becomes the obvious effect. 1–2 lbs/week is typical. Hit a plateau? Hold the dose, don't immediately bump.

Week 12 — decide

Bloodwork: A1c, lipids, liver enzymes, fasting insulin. Visible weight change should be 5–10%. If the trajectory is flat at 12 weeks and you've titrated, this isn't your molecule.

Quit if

Pancreatitis-like pain (severe upper-abdominal, won't sit still): stop and call your doctor.
Gallbladder pain or persistent vomiting that won't resolve.
Severe muscle loss without resistance training (the 'GLP-1 face' is real — protein floor matters).
12 weeks at full dose with zero weight movement (rare, but real).

Identity

What it is.

Orforglipron is not a peptide — it's a small-molecule non-peptide GLP-1 receptor agonist. We include it because it sits on every weight-loss decision tree alongside the actual peptides, and the distinction matters.

Because it's a small molecule rather than a , it can be taken orally without the bioavailability problems that dog oral semaglutide. No special formulation, no fasting window, no injection. That's the entire pitch.

Developed by Eli Lilly, in late-stage trials as of mid-2026 for both type 2 diabetes and chronic weight management. Not yet FDA approved. If approved, it would be the first daily oral with the same general efficacy profile as the injectable class — which would meaningfully change who actually takes these drugs and for how long.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Orforglipron actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓

Mechanism

Mechanism.

Mechanism · in the Orforglipron report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓

Evidence

Evidence. What we actually know in humans.

Evidence · in the Orforglipron report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓

Human-Evidence Factbox

FDA status

$19 ↓

Phase 3 ACHIEVE-1 (T2D, 36 mg, 40 wk)

$19 ↓

Phase 3 ATTAIN-1 (obesity, 36 mg, 72 wk)

$19 ↓

Dosing

$19 ↓

Food restrictions

$19 ↓

Expected approval window

$19 ↓

Dose

Dose. The actual protocol.

Dose · in the Orforglipron report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.

Get the report · $19 ↓

Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Orforglipron report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.

Get the report · $19 ↓

Safety

Safety. Side effects.

Safety · in the Orforglipron report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓

Editorial Position

Editorial position.

Editorial Position · in the Orforglipron report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓

Citations

Citations.

+Show all 60 citations

The Orforglipron Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.

Compare tiers →